Deproteinized dialysate from the blood of dairy calves
Ingredients 1 tablet contains: Active substance: deproteinized hemoderivat from calf blood 200 mg, Excipients: magnesium stearate, povidone K90, talc, cellulose, Shell composition: acacia gum, mountain glycolic wax, hypromellose phthalate, diethyl phthalate, dye quinoline yellow macrogol 6000, povidone K30, sucrose, talc, titanium dioxide.
Antihypoxant, is a hemoderivat, which is obtained by dialysis and ultrafiltration (penetrate compounds with a molecular mass of less than 5,000 daltons). It has a positive effect on glucose transport and utilization, stimulates oxygen consumption (which leads to stabilization of plasma membranes of cells during ischemia and reduction of lactate formation), which underlies the antihypoxic action, which begins to manifest itself at the latest 30 minutes after ingestion and reaches a maximum on average after 3 h (2-6 h). Actovegin increases the concentration of ATP, ADP, phosphocreatine, as well as amino acids (glutamate, aspartate) and GABA. The effect of the drug Actovegin on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of glucose transport and oxidation are important in the treatment of diabetic polyneuropathy. In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin reliably reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness of the lower extremities). Disorders of sensitivity are objectively reduced, the mental well-being of patients improves.
Using pharmacokinetic methods, it is impossible to study the pharmacokinetic characteristics (absorption, distribution, elimination) of the active ingredients of the drug Actovegin, since it consists only of the physiological components that are usually present in the body. So far, no decrease in the pharmacological efficacy of hemoderivate in patients with altered pharmacokinetics (including hepatic or renal failure, changes in metabolism associated with old age, due to the peculiarities of metabolism in newborns) has not been found.
Combined therapy of metabolic and vascular disorders of the brain (various forms of cerebral circulatory insufficiency, dementia, TBI). peripheral (arterial and venous) vascular disorders and their consequences (angiopathy, trophic ulcers), diabetic polyneuropathy.
Decompensated heart failure. Pulmonary edema. Oliguria Anuria. Fluid retention in the body. Hypersensitivity to the drug. Hypersensitivity to similar drugs.
Use during pregnancy and lactation
Use of the drug Actovegin during pregnancy and lactation is allowed, but caution should be exercised.
Dosage and administration
Actovegin is taken inside, 1-2 pills 3 times a day, without chewing, before meals with a small amount of liquid. The duration of treatment should be from 4 to 6 weeks.
Allergic reactions (for example, urticaria, edema, drug fever). In such cases, treatment with the drug Actovegin must be stopped. If necessary, conduct standard therapy of allergic reactions (antihistamines and / or corticosteroids).
Information about drug overdose Actovegin not provided.
Interaction with other drugs
Drug interaction drug Actovegin not installed.
With the development of allergic reactions taking Actovegin should be discontinued. If necessary, conduct standard therapy of allergic reactions (antihistamines and / or corticosteroids).